Presented by Julia Malkowski, ND, DC | April 1, 2026 at 12 PM Pacific

Methylation is a fundamental biochemical process with far-reaching implications for human health. This presentation will offer an in-depth exploration of methylation, its clinical significance, and the impact of methylation imbalances on health outcomes.

Methylation is involved in cardiovascular health, detoxification, neurotransmitter synthesis, hormone metabolism, DNA expression, immune modulation and fetal development. Analyzing key methylation biomarkers provides valuable insight into human physiology. Plasma levels of methionine, s-Adenosyl methionine (SAM), s-Adenosyl homocysteine (SAH), homocysteine, cystathionine and cysteine provide a functional assessment of the methylation cycle. Attendees will walk away with an understating of these biomarkers, enhanced understanding of methylation dynamics and their impact on clinical outcomes.

Learning Objectives:

• Understand the role of methylation in human physiology
• Comprehend objective biomarkers of the methylation cycle, including the methylation ratio, methionine, SAM, SAH, homocysteine, cystathionine and cysteine
• Explore the clinical significance of methylation imbalances
• Discuss case applications and therapeutic strategies based on methylation status

Presented by Jeannie Gorman, MS, CCN | May 6, 2026 at 12 PM Pacific

This webinar will explore how the GI360™ provides a comprehensive view of the microbiome and dysbiosis, with insights into GLP-1 signaling pathways. Learn practical applications for patients with GI, autoimmune, cardiovascular, neurological, or skin conditions, and discover how stool insights can guide better clinical outcomes.

Learning Objectives:

• Describe the GI360™ complimentary methodologies and applications
• Identify patients who benefit from stool testing
• Interpret markers of dysbiosis and GLP-1-modulating bacteria
• Apply targeted probiotics, soluble fiber, diet, and dysbiosis therapies to support microbiome health and GLP-1 signal pathways
• Explain the role of retesting for optimizing microbiome and GLP-1-related outcomes

Presented by Dr. Brandon Lundell, DC, APC, DABCI, IFMCP, Dip. Ac., NE, CAC | May 13, 2026 at 12 PM Pacific

Hormone imbalance is one of the most common presentations in functional medicine-but the wrong testing methodology can be more dangerous than no testing at all. When patients on transdermal or pellet hormone therapy show "normal" blood levels while their symptoms worsen, the problem isn't the patient-it's the test. Fat-soluble hormones applied to the skin bypass the liver, accumulate in adipose tissue, and bind to red blood cell membranes rather than circulating in plasma, making serum testing fundamentally unreliable for monitoring parenteral hormone therapy. In this one-hour webinar, Dr. Lundell walks practitioners through the complete Doctors Data hormone testing menu-including the Comprehensive Saliva Hormone Panel with melatonin, the HUMAP urinary metabolite profile, and the Basic Hormone Profile for cost-effective follow-up-equipping you to select the right test for every clinical scenario. You'll learn why morning cortisol is the single most important marker for HPA axis assessment, evidence-based strategies for elevated nighttime cortisol, and the emerging science of the gut-gonadal axis and its profound implications for fertility, menopause, and andropause. The presentation culminates with a case study of a menopausal woman made worse by hormone overtreatment and a critical examination of the popular claim that testosterone protects women against breast cancer-a myth that doesn't survive scrutiny of the actual data.

Learning Objectives:

• Navigate the Doctors Data hormone testing menu and select the appropriate panel based on clinical presentation, treatment monitoring needs, and cost considerations
• Explain why morning cortisol is the most clinically significant marker for HPA axis dysregulation and identify evidence-based interventions for elevated nighttime cortisol
• Describe the gut-gonadal axis and its implications for fertility, menopause, andropause, PCOS, and endometriosis in clinical practice
• Differentiate between blood, urine, and saliva hormone testing and articulate why serum testing is unreliable for monitoring parenteral hormone therapy
• Critically evaluate the claim that exogenous testosterone is breast cancer-protective in women and implement superior evidence-based strategies for breast cancer risk reduction